Tyra Biosciences, Inc. TYRA Right Of Use Asset
Right Of Use Asset at other companies
Other financials
Where this comes from
Reported directly by Tyra Biosciences, Inc. in its filing.
Tagged under the XBRL concept tyra:RightOfUseAsset.
The official record: Tyra Biosciences, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tyra Biosciences, Inc.'s right of use asset.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tyra Biosciences, Inc.'s right of use asset?
- Tyra Biosciences, Inc. (TYRA) reported right of use asset of $5.44M in Q1 2026.
- How has Tyra Biosciences, Inc.'s right of use asset changed year-over-year?
- Tyra Biosciences, Inc.'s right of use asset decreased by 8.5% year-over-year, from $5.95M to $5.44M.
- What is the long-term trend for Tyra Biosciences, Inc.'s right of use asset?
- Over 5 years (2020 to 2025), Tyra Biosciences, Inc.'s right of use asset has grown at a 101.2% compound annual growth rate (CAGR), from $169K to $5.57M.
- What does right of use asset mean?
- This metric represents the capitalized value of a company's right to use an underlying leased asset over the lease term, recognized on the balance sheet under non-current assets. It reflects the long-term commitment to leased properties or equipment, such as office space or laboratory facilities, essential for ongoing clinical-stage operations. Monitoring this value helps investors assess the scale of the company's long-term operating lease obligations and the associated asset base utilized to support research and development activities.